Navigation Links
New binding target for oncogenic viral protein

The DNA tumor virus simian virus 40 produces the Large T antigen which inactivates two of the cell's most important cancer-preventing proteins, p53 and pRb. In a study published in the Journal of Biological Chemistry, researchers at the Fred Hutchinson Cancer Research Center report the discovery of an additional target for T antigen--a protein called Fbw7.

The Fbw7 gene is located in a chromosomal region that is deleted in up to 30% of human tumors. "Fbw7 is itself an important tumor suppressor which makes it an attractive choice for inactivation by Large T," explained Dr. Markus Welcker, the study's first author.

The research appears as the "Paper of the Week" in the March 4 issue of the Journal of Biological Chemistry, an American Society for Biochemistry and Molecular Biology journal.

DNA tumor viruses proliferate by hijacking their host cell's DNA replication machinery. In order to do this, they have evolved mechanisms to override normal cellular replication controls. Simian virus 40 (SV40) accomplishes this task by producing the highly oncogenic large T antigen. This protein corrupts the cellular checkpoint mechanisms that guard cell division and the transcription, replication and repair of DNA. T antigen also inactivates some of the most important proteins that protect cells against malignant transformation, including tumor suppressor proteins p53 and pRb.

In the Journal of Biological Chemistry paper, Dr. Welcker and Dr. Bruce Clurman report that T antigen also binds to another tumor suppressor, Fbw7. This protein is part of a ubiquitin ligase complex that adds ubiquitin to proteins to mark them for destruction by the cell. Fbw7 recognizes a destruction signal on certain proteins that need to be degraded and brings them in close proximity to the enzymes that attach ubiquitin. The proteins recognized by Fbw7 play key roles in cell division, cell growth, differentiation, and cell death.

"These proteins are also some of the
'"/>

Source:American Society for Biochemistry and Molecular Biology


Page: 1 2

Related biology news :

1. Ancient olfaction protein is shared by many bugs, offering new pest control target
2. A bacterial genome reveals new targets to combat infectious disease
3. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
4. Researchers identify target for cancer drugs
5. Study reveals candidate targets for anti-retroviral therapeutics
6. MUHC researchers make cancer target breakthrough
7. Future diabetes drugs may target new protein interaction
8. Smart drug targets deadly brain cancer
9. NHGRI targets 12 more organisms for genome sequencing
10. While on trail of dioxin, scientists pinpoint cancer target of green tea
11. Moffitt-USF head toward first human trials of anti-cancer drug that targets protein AKT

Post Your Comments:
(Date:11/20/2009)... - Bacteria possess an ingenious mechanism for pre... the cell. This is the new finding of a team of bi...e sciences research institute in Flanders, Belgium... scientists made this discovery by modifying the D... By means of this model organism, they have uncove...
(Date:11/20/2009)...Research Center (ERC) has been awarded a grant fro...ethods of recovering and reusing the heat that wou...ression process in a carbon capture system. The go... capture and sequestration, or storage (CCS), and ...emitted into the atmosphere by coal-fired power pl...
(Date:11/19/2009)...which cultivate fungus for food, have many remarka... list: the ant farmers, like their human counterpa...eir gardens grow. The finding, reported this week ...eviously unknown symbiosis between ants and bacter...have come to dominate the American tropics and sub...
Breaking Biology News(10 mins):Biologists discover bacterial defense mechanism against aggressive oxygen 2Lehigh receives grant to reduce cost of carbon capture at coal-fired power plants 2Lehigh receives grant to reduce cost of carbon capture at coal-fired power plants 3Like humans, ants use bacteria to make their gardens grow 2FDA Awards Three Grants Designed to Stimulate Development of Pediatric Medical Devices 57798 1FDA Awards Three Grants Designed to Stimulate Development of Pediatric Medical Devices 57798 2FDA Awards Three Grants Designed to Stimulate Development of Pediatric Medical Devices 57798 3GeoVax Labs Requests pre IND Meeting With FDA 14181 1GeoVax Labs Requests pre IND Meeting With FDA 14181 2GeoVax Labs Requests pre IND Meeting With FDA 14181 3Family Planning for the Worlds Poor 3A Who Will Pay 3F 57794 1Family Planning for the Worlds Poor 3A Who Will Pay 3F 57794 2
...iversity of Alaska Fairbanks neuroscientists study...resent their research findings at the 7th Conferen...ms in New York Aug. 19-22, 2008. , The scientists... at the UAF Institute of Arctic Biology, which is ...se goal is to expand and stimulate basic neuroscie...
... 2008 -- Elsevier, a leading global healthcare and...lists in The Elsevier Grand Challenge, a competiti...tools innovating how Life Sciences information is ...ts were chosen by a distinguished panel of judges ...nge of approaches involving semantics, visualizati...
...8, 2008 With oil prices skyrocketing, the search ...arch published this month in Agronomy Journal ex... Corn stover is made up of the leaves and stalks ...rvesting the edible corn grain. Corn stover could ...y 2030. , Scientists with the USDA-ARS Agroecosy...
Other Biology News:Stroke and SIDS in Alaska topics of neuroscience conference 2Elsevier announces 10 semi-finalists for the Elsevier Grand Challenge 2Elsevier announces 10 semi-finalists for the Elsevier Grand Challenge 3
(Date:11/19/2009)... World,s Top Gene Synthesis...rtium (IGSC) to Coordinate Best Practices in Risk ...rcent of Worldwide Gene Synthesis Capacity , ...ive of the world’s leading gene synthesis co...pply a common screening protocol to promote biosec...
(Date:11/18/2009)..., , DAVIS, Calif., Nov. 18 Mar...ery, development and commercialization of effectiv...products, announced that it has been named an IC20...es, oldest and largest national angel investing gr...rformance leading to rewarding results for all sta...
(Date:11/18/2009)..., CHAMPAIGN, Ill. Imagine a polka-dotted postage ... toxins simply by changing colors. , As reported...istry , Kenneth Suslick and his team at the Univer... for the general detection of toxic industrial che... and works by visualizing odors. This sensor arr...
(Date:11/18/2009)..., , Vernier,s experience in data analysis ... (TM) program kits and curricula provide s...on ,, BEAVERTON, Ore., Nov. 18 /PRNewswire/ -... educational science interfaces, sensors, and soft...al manufacturer and distributor of life science re...
Breaking Biology Technology:World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4Marrone Bio Innovations Named an IC20 Company 2Opto-electronic nose sniffs out toxic gases 2Opto-electronic nose sniffs out toxic gases 3Vernier and Bio-Rad to Offer Enhanced Solutions for Biotechnology Education 2
...l/ - AEterna Zentaris Inc.,(NASDAQ: AEZS ; TSX: A...,endocrine therapy and oncology, today reported th...y,s first efficacy trial of its Phase 3 program,in...us enlargement of the,prostate, with its flagship ...approximately 600 patients primarily in the United...
....,(SWX: ARPN) today announced that it will host a ...m CET. In this conference call, a leading expert w...he area of anti-infective,drugs as well as the out...gs Advisory Committee. During that meeting, the co... trial design for both mild/moderate and,moderate/...
...n Association for Cancer Research ...ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ) announ...s,registrational bioequivalence clinical study of ...n Association for Cancer Research (AACR),Annual Me...kinetic,equivalence observed between an emulsion f...
Other Biology Technology:AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia 3AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia 4Arpida Announces Conference Call on 17 April 2Arpida Announces Conference Call on 17 April 3ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study 2ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study 3ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study 4ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study 5
Anti-p14ARF / p16Beta Ab-1 Polyclonal Antibody, Unconjugated from Lab Vision
Mouse Anti-Human MCAF-(MCP-1) Antibody, from Abazyme
Mouse Anti-Human Gastric Carcinoma Marker [BY-1] Monoclonal Antibody, Unconjugated, Clone 3H11 from Santa Cruz Biotechnology, Inc.
Goat Anti-LTBP-1 (E-20) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Biology Products: